NDAORALTABLET
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
21
Mechanism of Action
5-HT 1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT 1F receptor; however, the precise mechanism is unknown.
Indications (1)
Clinical Trials (5)
A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants
Started May 2021
47 enrolled
Healthy
A Study of Lasmiditan in Healthy Volunteers
Started Feb 2021
97 enrolled
Healthy
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Started Jun 2020
566 enrolled
Migraine
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Started Jun 2020
851 enrolled
Migraine
A Study of Lasmiditan in Healthy Chinese Participants
Started Nov 2019
36 enrolled
Healthy
Loss of Exclusivity
LOE Date
Jul 6, 2040
174 months away
Patent Expiry
Jul 6, 2040